Semaglutide Dosage: What the Clinical Trials Show in 2026
Semaglutide is the most extensively studied GLP-1 receptor agonist for weight management, with Phase 3 clinical trial data across thousands of participants. The dose escalation schedules, the weight loss responses at each dose level, and the difference between subcutaneous and oral formulations are all documented in peer-reviewed trial data.
This guide covers what the clinical trials actually used — not anecdotal protocols. These are the doses from published research, the weight loss outcomes at each level, and the factors that determine whether dose escalation is appropriate. This is an informational overview of published research — not medical advice or dosing instruction for human use.
How Semaglutide Dosing Works: The Biological Rationale
Semaglutide doses are escalated gradually rather than started at therapeutic levels because GLP-1 receptor agonism at the hypothalamic and GI levels produces dose-dependent side effects — primarily nausea and GI discomfort — that are severe at initial exposure and diminish substantially as the GI tract adapts. The escalation schedule is designed to titrate slowly enough that GI tolerance develops before reaching the doses where weight loss effect is maximized.
Why dose matters for weight loss outcomes:
GLP-1 receptor agonism produces dose-dependent appetite suppression. At lower doses, the primary effect is improved glycemic control (reduced glucose excursions, improved insulin secretion). At higher doses (1.7–2.4mg for subcutaneous formulations), the hypothalamic appetite suppression effect becomes primary — producing the caloric restriction that drives meaningful weight loss. This is why the FDA approved separate dose ranges for Type 2 Diabetes (Ozempic: up to 2.0mg) versus obesity (Wegovy: up to 2.4mg).
Subcutaneous Semaglutide: The STEP Trial Dose Escalation Schedule
The STEP clinical trial program used a standardized dose escalation schedule for the 2.4mg subcutaneous formulation (Wegovy). This is the most-replicated protocol in the literature:
| Week | Dose |
|---|---|
| 1–4 | 0.25mg once weekly |
| 5–8 | 0.5mg once weekly |
| 9–12 | 1.0mg once weekly |
| 13–16 | 1.7mg once weekly |
| 17+ | 2.4mg once weekly (maintenance) |
Dose flexibility note: In STEP trials, participants who could not tolerate dose escalation were permitted to remain at the prior dose level for an additional 4 weeks before attempting escalation again. This accommodation is important — slower escalation did not eliminate participants from the study and produced similar final weight loss outcomes.
Weight Loss Outcomes by Dose Level
The STEP trials documented weight loss at each timepoint, which corresponds to different accumulated dose exposure:
- At 16 weeks (most participants at 1.7mg): approximately 8–10% mean body weight reduction
- At 20 weeks (most participants at 2.4mg): approximately 10–12% mean body weight reduction
- At 68 weeks (STEP 1 primary endpoint at 2.4mg maintenance): 14.9% mean body weight reduction vs 2.4% placebo
The 2.4mg maintenance dose is where the plateau effect of semaglutide manifests — weight continues to decline until approximately weeks 60–65 before stabilizing.
STEP 3: Higher Response with Behavioral Intervention
STEP 3 added intensive behavioral therapy alongside the same 2.4mg protocol. The combined outcome was 16.0% mean body weight reduction at 68 weeks — suggesting behavioral reinforcement augments pharmacological appetite suppression rather than them being redundant.
STEP 5: 2-Year Maintenance Data
STEP 5 was the extension study at 104 weeks. Mean body weight reduction was 15.2% at 104 weeks, demonstrating durability of the weight loss effect with continued dosing. This is clinically significant because it demonstrates maintenance — not regain — with ongoing administration.
Subcutaneous Semaglutide for Type 2 Diabetes: The Ozempic Dosing Schedule
The diabetes indication (Ozempic) uses a different top-end dose and different escalation targets:
| Phase | Dose |
|---|---|
| Weeks 1–4 | 0.25mg once weekly |
| Weeks 5–8 | 0.5mg once weekly |
| After week 8 | 1.0mg once weekly (standard maintenance) |
| If additional glycemic control needed | 2.0mg once weekly |
The SUSTAIN trial program documented glycemic outcomes at each dose level:
- 0.5mg: Mean HbA1c reduction of approximately 1.4%
- 1.0mg: Mean HbA1c reduction of approximately 1.6%
- 2.0mg (SUSTAIN-6/SUSTAIN FORTE): Mean HbA1c reduction of approximately 1.8–2.1% with additional weight loss vs 1.0mg
Weight loss in the diabetes population at 1.0mg was approximately 4–6% body weight — lower than the obesity population at 2.4mg, reflecting differences in baseline metabolic state and study design.
Oral Semaglutide: A Fundamentally Different Dosing Framework
Oral semaglutide (Rybelsus) requires a completely different dose framework because subcutaneous and oral administration are not interchangeable by mg equivalence. Oral bioavailability is approximately 1% — the SNAC absorption enhancer in Rybelsus partially compensates, but the pharmacokinetics are entirely different.
Oral semaglutide doses for T2D (Rybelsus):
| Phase | Dose |
|---|---|
| Weeks 1–4 | 3mg once daily (morning, fasting) |
| Weeks 5–8 | 7mg once daily |
| Week 9+ | 14mg once daily (maintenance) |
These doses are not equivalent to subcutaneous doses. The 14mg oral dose produces lower peak plasma concentrations than 1.0mg subcutaneous. Administration requirements for oral semaglutide are strict: taken on an empty stomach with 120mL water, minimum 30 minutes before eating or drinking, because food drastically reduces absorption.
Weight loss comparison (oral vs SubQ):
The PIONEER oral semaglutide trials showed weight loss of approximately 4.4kg at 14mg at 26 weeks — meaningfully less than subcutaneous at equivalent timepoints. This is not a formulation failure but an expected consequence of the bioavailability difference. Oral semaglutide was developed for metabolic/diabetes control with the weight benefit secondary; subcutaneous at 2.4mg was optimized for maximum weight outcomes.
Dose Escalation in Practice: What the Trials Show About Tolerability
GI Side Effects by Dose
The STEP trial safety data documented GI adverse event rates:
| Dose Phase | Nausea Prevalence |
|---|---|
| 0.25mg (weeks 1–4) | ~20% |
| 0.5mg (weeks 5–8) | ~25% |
| 1.0mg (weeks 9–12) | ~30% |
| 2.4mg (maintenance) | ~15% (habituated) |
Nausea peaks during escalation and then decreases substantially as receptor-level adaptation occurs. The most common reason participants discontinued in STEP trials was GI tolerability during escalation — not at maintenance dose.
Slower Escalation Outcomes
A post-hoc analysis of STEP data showed that participants who required dose-escalation pauses (remaining at a lower dose for additional weeks) ultimately achieved similar 68-week weight loss outcomes as those who escalated on schedule. This suggests weight loss outcomes are determined primarily by the maintenance dose achieved, not escalation speed.
Weight Loss Plateau and Dose Considerations
At 2.4mg maintenance dosing, most participants reach their weight loss nadir between weeks 60 and 68. This plateau reflects a new energy balance equilibrium at the level of appetite suppression the 2.4mg dose produces — it is not tolerance to the drug itself. Published data does not demonstrate dose escalation beyond 2.4mg improving outcomes in the obesity population.
For researchers studying weight regain: the STEP 1 follow-up study showed that weight regain of approximately 11.6% body weight occurred within 1 year of discontinuation, with two-thirds of weight lost regained — consistent with GLP-1 receptor agonism being appetite-suppressive rather than metabolic set-point-resetting.
Semaglutide vs Tirzepatide: Dosing Comparison
Understanding where semaglutide sits in the GLP-1 class requires comparison with the next-generation compound:
| Metric | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Max dose | 2.4mg weekly | 15mg weekly |
| Phase 3 weight loss | ~14.9% | ~20.9% |
| Escalation duration | 16 weeks to maintenance | 20 weeks to maintenance |
| GI tolerance profile | Similar class effects | Similar class effects |
Tirzepatide's dose escalation schedule for the 15mg target:
| Phase | Dose |
|---|---|
| Weeks 1–4 | 2.5mg |
| Weeks 5–8 | 5mg |
| Weeks 9–12 | 7.5mg |
| Weeks 13–16 | 10mg |
| Weeks 17–20 | 12.5mg |
| Week 21+ | 15mg maintenance |
The longer escalation period for tirzepatide reflects its higher target dose and the additional GIP receptor effects.
Why Purity Matters for Dosing Accuracy
For research using peptide-grade semaglutide from verified suppliers, purity has direct implications for effective dose delivered. Third-party COA documentation is the minimum standard for evaluating whether a compound meets its stated specifications.
Dose accuracy calculation:
If a vial is labeled 5mg and the third-party COA reports 90% purity, the effective active content is 4.5mg — a 10% dosing variance. At 80% purity, the effective content is 4.0mg — a 20% variance. At lower purity levels, dose escalation protocols become unreliable because each unit administered contains a different effective amount of active compound.
For injectable research compounds, this matters more than for oral formulations where variable absorption already introduces variance. Subcutaneous injection pharmacokinetics are predictable; compound purity variance is avoidable with COA verification.
Key elements to verify in a semaglutide COA:
- HPLC purity (not just identity test): should show the purity percentage, not just confirm the compound is present
- Third-party testing: issued by a laboratory independent of the supplier, not an internal quality document
- Batch-specific documentation: a COA from a prior lot doesn't validate the current lot
See our COA verification guide for how to evaluate supplier documentation.
Frequently Asked Questions
What is the standard semaglutide dose for weight loss?
The FDA-approved dose for obesity management (Wegovy) is 2.4mg subcutaneous once weekly at maintenance. This follows a 16-week escalation starting at 0.25mg. The STEP 1 trial showed 14.9% mean body weight reduction at 68 weeks at this dose. For Type 2 Diabetes (Ozempic), the standard maintenance doses are 1.0mg or 2.0mg weekly.
How long does it take to reach maximum dose?
The standard STEP protocol reaches 2.4mg maintenance at week 17 — after four escalation phases of four weeks each. Participants who cannot tolerate a dose step can extend each phase by an additional four weeks. The escalation timeline affects when maximum weight loss effect begins, but the 68-week outcomes are similar regardless of escalation speed.
Does a higher dose always mean more weight loss?
Within the studied dose range, yes — there is a dose-response relationship. SUSTAIN trials showed 2.0mg produced better glycemic control than 1.0mg in diabetes. The obesity trials show 2.4mg produces more weight loss than lower maintenance doses. However, going above approved dose ranges has not been studied for safety or efficacy and is outside the published evidence base.
What happens when semaglutide is stopped?
The STEP 1 extension data showed weight regain of ~11.6% within 1 year of stopping — approximately two-thirds of lost weight returned. This is consistent with the mechanism: semaglutide produces continuous appetite suppression during administration, which ends when dosing stops. The biological drivers of obesity reassert once the GLP-1 agonism is removed.
Is oral semaglutide (Rybelsus) as effective as the injection?
No. Oral bioavailability is approximately 1% without SNAC enhancement and remains low even with it. The 14mg oral dose produces less weight loss than 1.0mg subcutaneous in parallel-design comparisons. Oral semaglutide is useful for metabolic/glycemic management (the Rybelsus approval) but was not developed or studied as an obesity agent at the same efficacy level as the subcutaneous formulation.
How does semaglutide dosing compare to retatrutide?
Retatrutide's Phase 2 data used doses up to 12mg weekly (subcutaneous), with the 12mg arm showing 24.2% mean body weight reduction at 48 weeks vs 14.9% for semaglutide at 68 weeks. Retatrutide is not yet FDA-approved — the Phase 3 TRIUMPH program was ongoing as of 2026. The dose ranges and escalation schedules for retatrutide are still being characterized in the ongoing trials.
Current Pricing
All compounds listed are sold by suppliers for research purposes only and are not intended for human use, food, or drug applications. This content is informational and does not constitute medical advice. Best Pep Prices does not sell compounds and is not compensated by any supplier for rankings.
Compare live prices across 60+ verified research peptide suppliers